Merck KGaA Questioned In India

3 February 1997

The Indian subsidiary of the German pharmaceuticals group, Merck KGaA,is being questioned by the country's Monopolies and Restricitve Trade Practices Commission for allegedly not stipulating to its dealer that drugs and medicines could be sold at prices lower than those indicated in the price list. The MRTPC issued the notice of enquiry to E Merck (India) about restrictive trade practices after an application was filed by the director general of the MRTPC's investigation section.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight